Pharma Journalist -

Confo Therapeutic announced a worldwide licensing agreement with Eli Lilly and Company for Confo’s clinical stage CFTX-1554 and back-up compounds. CFTX-1554, a novel inhibitor of the…
Read More...

Nexus Pharmaceuticals, Inc. announced that it has received US Food and Drug Administration (FDA) approval for EMERPHED (ephedrine sulfate injection) in 25mg/5mL and 50mg/10mL…
Read More...

Oragenics, Inc. announced that the Company has entered into an exclusive global license agreement with Inspirevax Inc. for its novel intranasal mucosal adjuvant, BDX301, for the…
Read More...

The European Commission has granted marketing authorization in the European Union (EU) for Nubeqa (darolutamide), an oral androgen receptor inhibitor (ARi), plus androgen deprivation…
Read More...

ImmunoGen, Inc. announced a global, multi-target license and option agreement whereby it granted Vertex Pharmaceuticals (Vertex) (NYSE: VRTX) rights to conduct research using…
Read More...

BioNxt Solutions Inc. is pleased to report that it has executed an agreement to carry out its comparative drug absorption study for the Company’s transdermal (“TDS”) Rotigotine patch…
Read More...

Regeneron Pharmaceuticals, Inc. and Sanofi announced that the U.S. Food and Drug Administration (FDA) has approved Kevzara (sarilumab) for the treatment of polymyalgia rheumatica (PMR),…
Read More...

Sunshine Biopharma Inc. announced the signing of an exclusive worldwide license agreement (the “License Agreement”) with the University of Arizona. The License Agreement grants Sunshine…
Read More...

Tevard Biosciences, Inc., the pioneer of tRNA-based therapies for severe genetic diseases, announced a four-year global research collaboration with Vertex Pharmaceuticals Incorporated…
Read More...

Reata Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (“FDA”) has approved SKYCLARYS (omaveloxolone) for the treatment of Friedreich’s ataxia in adults and…
Read More...